Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis

Authors

Mark T. Osterman, University of Pennsylvania
Faten N. Aberra, University of Pennsylvania
Raymond Cross, University of Maryland - Baltimore
Steven Liakos, South Jersey Gastroenterology
Robert McCabe, Minnesota Gastroenterology
Ira Shafran, Shafran Gastroenterology Center
Douglas Wolf, Atlanta Gastroenterology Associates
Robert Hardi, George Washington University
Lisa Nessel, University of Pennsylvania
Colleen Brensinger, University of Pennsylvania
Erin Gilroy, University of Pennsylvania
James D. Lewis, University of Pennsylvania

Document Type

Journal Article

Publication Date

11-2014

Journal

Clinical Gastroenterology and Hepatology

Volume

Volume 12, Issue 11

Inclusive Pages

1887-1893

APA Citation

Osterman, M.T., Aberra, F.N., Cross, R., Liakos, S., McCabe, R. et al. (2014). Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology, 12(110, 1887-1893.

Peer Reviewed

1